Bernstein Initiates Coverage On Revolution Medicines with Market Perform Rating, Announces Price Target of $151

Revolution Medicines

Revolution Medicines

RVMD

0.00

Bernstein analyst Jeffrey Walch initiates coverage on Revolution Medicines (NASDAQ: RVMD) with a Market Perform rating and announces Price Target of $151.